Gedatolisib triplet cut the risk of disease progression or death by 76% vs. fulvestrant. Median progression-free survival improved to 9.3 months with the triplet vs. 2.0 months with fulvestrant. The market's back, and these 3 income stocks are thriving. See them here→ Celcuity Inc.

CELC

<p>Gedatolisib triplet cut the risk of disease progression or death by 76% vs. fulvestrant. Median progression-free survival improved to 9.3 months with the triplet vs. 2.0 months with fulvestrant. The market's back, and these 3 income stocks are thriving. See them here→ Celcuity Inc.</p>

Celcuity 股票因重度预处理乳腺癌的突破性试验数据而大幅上涨